Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 0.3% - Time to Sell?

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report)'s share price fell 0.3% during mid-day trading on Thursday . The company traded as low as $3.01 and last traded at $3.06. 43,453 shares were traded during trading, a decline of 12% from the average session volume of 49,258 shares. The stock had previously closed at $3.07.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, April 29th.

Alpha Tau Medical Stock Performance

The firm has a market cap of $259.55 million, a price-to-earnings ratio of -6.65 and a beta of 0.99. The company has a quick ratio of 5.81, a current ratio of 5.81 and a debt-to-equity ratio of 0.10. The stock has a fifty day moving average price of $3.03 and a 200-day moving average price of $2.99.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings data on Monday, May 19th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. On average, analysts expect that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in shares of Alpha Tau Medical in the 1st quarter worth about $53,000. Renaissance Technologies LLC grew its position in shares of Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after acquiring an additional 26,800 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after purchasing an additional 25,770 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC raised its stake in Alpha Tau Medical by 601.4% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock valued at $568,000 after acquiring an additional 194,055 shares in the last quarter. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.